Studies of lifestyle advice and dietary intervention show that although moderate, clinically significant weight loss is achievable and results in concomitant improvements in comorbidities, it is invariably transient and recidivism is almost universal. Pharmacotherapeutic options do show promise but are currently inadequate to address many obesity-associated comorbidities. Bariatric surgery consistently results in considerable improvement in weight, alongside a remarkable amelioration in comorbid conditions. Here we describe the physiology of energy balance and the putative mechanisms of change in weight set point following bariatric surgical procedures such as Roux-en-Y gastric bypass and adjustable gastric banding.
Introduction
The rise in obesity and its morbid associations is one of the most pressing issues facing the medical and scientific community. The prevalence of obesity among adults worldwide has risen by 75% since 1980, 1 and has been rising even faster in children. 2 The threat to public health services is unparalleled and obesity has become a socioeconomic time bomb as a result of its well known cardiovascular, metabolic, reproductive, neoplastic, musculoskeletal and psychosocial complications. 3, 4 The target set by the United Kingdom House of Commons Health Select Committee in 1992 was 'for fewer than 6% of men and 8% of women to be obese by 2005'. 5 The inadequacies of current treatments for obesity are illustrated irrefutably by the current figures, which stand at over 25% for women and 23% for men in the UK. 6 Studies of lifestyle advice and dietary intervention show that although moderate, clinically significant weight loss is achievable and results in concomitant improvements in comorbidities, it is invariably transient and recidivism is almost universal. 7 Pharmacotherapeutic options are currently inadequate. Only orlistat and sibutramine are approved in the UK for the treatment of obesity, and they usually result in a 5-10% weight loss when used in conjunction with lifestyle and dietary advice. 8 The value of surgery as a treatment for obesity
Bariatric surgery consistently results in considerable reduction in weight, alongside a remarkable amelioration in comorbid conditions. 9 Importantly two landmark studies have recently shown that bariatric surgery of all types also decreases long-term mortality by 29-40%. 10, 11 Roux-en-Y gastric bypass (RYGB), the most common bariatric operation, results in 20-40% weight loss initially, the majority of which is maintained over at least 15 years. 12 Laparoscopic adjustable gastric banding (LAGB) typically results in slightly less weight loss, around 15-30%. 9 There is a substantial body of literature showing the beneficial effect of bariatric surgery on obesity associated comorbidities, including hypertension, dyslipidaemia, non-alcoholic steatohepatitis, sleep apnoea, asthma, cardiac dysfunction, arthritis and infertility. 13, 14 In addition, psychological disorders associated with obesity improve, alongside both quality of life and economic productivity. 4, 15, 16 Particularly impressive is the rapid and complete resolution of type 2 diabetes in B80% of patients who undergo RYGB. Interestingly, this resolution seems to be independent of weight loss, and occurs within days of surgery.
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The physiological control of energy homoeostasis
Evidence suggests Humans have a complex physiological 'adipostatic' system that vigorously defends a set weight in the face of positive or negative energy balance. The hypothalamus takes centre stage in the adipostat. It integrates both the long-and short-term signals about energy flux and orchestrates the compensatory responses to deviation from the hypothalamic set point. 18 Several peripheral messengers have been discovered that participate in the regulation of energy homoeostasis. Leptin, for example, is a hormone that circulates in proportion to fat mass and acts at the hypothalamus to promote negative energy balance by decreasing food intake and increasing energy expenditure. 19 A subset of peripheral messengers, termed gut hormones, have been implicated in the mechanism of weight loss following bariatric surgery. Among them, ghrelin, peptide tyrosine tyrosine (PYY), glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) have all been identified as potential players.
Ghrelin is a 28-amino-acid acetylated peptide secreted primarily by the stomach and proximal small intestine. It is found in the highest concentrations in the fundus of the stomach. It plays a role in both long-and short-term energy homoeostasis. 20 The circulating levels of ghrelin increase before each meal and decrease afterwards, implicating it in meal initiation. 20 In addition, the circulating ghrelin concentration is inversely proportional to body mass index and is influenced by change in body weight. 21 Ghrelin administration to humans increases energy intake and promotes weight gain. 22 Peptide tyrosine tyrosine is a satiety hormone secreted from enteroendocrine L-cells found predominantly in the distal gut. PYY is released postprandially and circulates in two forms: PYY1-36 and PYY3-36. 23 Intravenous PYY3-36 infusion has been shown to increase satiety and reduce food intake in humans. 23 The enteroglucagons are a group of gut hormones, which are all produced by differential splicing of a common precursor molecule, preproglucagon, by proconvertase 1. They include glucagon, GLP-1, GLP-2 and oxyntomodulin. 24 Plasma GLP-1 concentration peaks postprandially. Peripheral administration of GLP-1 has been shown in humans to inhibit appetite and augment the release of insulin. 25 Oxyntomodulin, similar to GLP-1, is released postprandially, and has been shown to reduce food intake when regularly administered to humans. 26 GLP-2's principal role seems to be as an intestinal trophic factor, and does not influence appetite physiologically. 25 GLP-2 may play a role in gut adaptation following RYGB to prevent malabsorption. The vagus nerve is of particular importance to bariatric surgery as it innervates the gastrointestinal tract extensively. Vagal nerve endings, the majority of which are afferent sensory fibres, are found throughout the oesophagus, stomach, liver, and both the small and large intestines, the majority of which are afferent sensory fibres. 27 Vagal signalling is involved in the short-term regulation of feeding. It transmits information from stretch and chemoreceptors, which are activated by the presence of nutrients in the stomach and the intestine. 28 Gut hormone signalling and the vagal nerve are closely intertwined. CCK was the first anorexigenic gut hormone to be discovered. 29 Released from the proximal small intestine postprandially, it is thought to act as an early satiety factor through CCK receptors on the vagus nerve. 30 All of these signals are relayed to a number of CNS structures, including the nucleus tractus solitarius, a brainstem nucleus know to be important in mediating food intake. 18 When an individual attempts to lose weight either by dieting or by medication, the body perceives this as a period of reduced food availability and orchestrates the various compensatory responses, all of which have the single aim of acheving positive energy balance. Bariatric surgery seems to circumvent the compensatory responses to negative energy balance, and the stable long-term maintenance of a substantially lower body mass index ensues. The mechanisms of weight loss following bariatric surgery are incompletely understood, but recent advances in our understanding of both central mechanisms and the role of gut hormones in regulating energy homoeostasis have brought us closer to an answer, and therefore closer to the attractive goal of mimicking the effects of bariatric surgery with pharmacotherapy.
Bariatric operations
Historically, on the basis of early theories about the mechanism of weight loss, the various surgical options for treating obesity were classified into restrictive, malabsorptive or hybrid procedures. 17 Although convenient, this classification system may be misleading. Malabsorptive procedures typically bypass a section of the small intestine and were thought to result in weight loss because of the decreased absorptive mucosal surface area and therefore malabsorption. The jejuno-ileal bypass (JIB) is the predecessor of the modern malabsorptive bariatric techniques. It involved in rearrangement of the small bowel so that nutrients passed directly from the proximal jejunum to the terminal ileum. Although weight loss was considerable, patients suffered from serious complications, such as protein malnutrition, oxalate nephrolithiasis, metabolic bone disease, vitamin deficiencies, and, in the most severe cases, hepatic failure. 31 The complications were thought to be caused by bacterial overgrowth in the relatively long-blind loop created by the JIB. The RYGB is the most frequently carried out bariatric operation. 32 It is considered by the American National
Institute of Health to offer the best balance of weight loss and comorbidity resolution against risks of complication. It was classified as a 'hybrid' operation because it tried to combine elements of both restrictive and malabsorptive procedures, and, unlike the JIB, has no blind loops. The surgery involves using a stapler to divide the stomach, creating a small (15-30 cm 2 ), vertically orientated stomach pouch. The pouch is then anastomosed to the distal limb of the jejunum, which is divided 30-75 cm from the ligament of Treitz. The now incongruent duodenum and proximal jejunum form the biliary limb, and are anastomosed to the alimentary limb at a variable distance
Mechanisms of weight loss after bariatric surgery JA Tadross and CW le Roux from the gastrojejunostomy, usually 75-150 cm. This results in food bypassing 95% of the stomach, the entire duodenum and a section of the jejunum. Vertical banded gastroplasty and adjustable gastric banding were termed restrictive procedures because it was thought that weight loss was caused by the restriction imposed on food intake by the artificial constriction of the stomach. When a patient undergoes LAGB, this effect is achieved by encircling the proximal stomach with an insufflatable silastic band connected to a subcutaneous port. Initially, the band offers negligible gastric restriction, but with time the band aperture is adjusted through the subcutaneous port to produce optimal appetite suppression and weight loss. It is currently the procedure of choice for many as it is associated with very low postoperative morbidity and mortality and is far less invasive and far more amenable to reversal than the RYGB. 33 The mechanisms of weight loss after RYGB It was thought initially that RYGB mechanically caused malabsorption because pancreatic and biliary secretions only mixed with food in the short common segment of the small bowel, and that the ensuing undernutrition explained the weight loss. The standard proximal RYGB may result in some degree of malabsorption initially, but this quickly resolves as the gut adapts to its new arrangement. 34 The long limb RYBG, usually reserved for the exceptionally obese, is designed to cause a clinically significant degree of malabsorption. Serum markers of nutritional status, such as albumin and faecal fats, are normal after standard RYGB. 35 Interestingly, randomised, prospective studies show that the amount of weight lost following RYGB is similar to that lost following JIB, despite the fact that significant malabsorption follows JIB, 36 implying that there must be some other mechanism at play effecting weight loss after RYGB. In addition, it has been shown that malabsorption alone cannot fully explain the amount of weight lost after JIB. 37 Dumping syndrome can occur when sugary foods are consumed, and it has been suggested as a possible cause for weight loss after RYGB. Sugars are rapidly 'dumped' into the small intestine where they exert an intense-osmotic effect, drawing fluid from the circulation into the intestine. 38 The consequent decrease in circulating volume leads to reflex increases in the heart rate and causes palpitations. At the same time, an exaggerated incretin response causes symptoms of hypoglycaemia, 39 and what results is an acute syndrome characterised by diaphoresis accompanied by palpitations, bloating, nausea, and diarrhoea, which can be quite unnerving for the sufferer. 38 Dumping syndrome may aversively condition individuals against consuming high energy, sugar dense foods, and therefore contribute to weight loss. Clinically, it has been shown, however, that the amount of weight loss following RYGB correlates poorly with the severity of dumping syndrome, implying that it is unlikely to play a major role. 12 Impedance of the flow of food caused by gastric restriction after RYGB may contribute to weight loss. The presence of food within the small stomach pouch may also result in supramaximal gastric distension and therefore promote early satiety and reduced meal size. 40 Nevertheless, if this was the only factor at play, as individuals lost weight a compensatory mechanism would activate to increase food intake and reduce energy expenditure. Individuals would increase energy intake by eating more frequently and choosing energy-dense foods. In addition, prospective randomised studies have shown that the purely restrictive vertical banded gastrectomy operation produces a similar degree of gastric restriction to RYGB, but results in significantly less weight loss and less durability of weight loss. 41 The same compensatory mechanisms would be expected if patients lost weight simply through malabsorption. It has become apparent, however, that following RYGB individuals typically consume less food. They eat fewer meals and snacks, and especially fewer energy-dense foods; they typically shun high fat and high sugar foods. 42 The key question is, how does bariatric surgery overcome an individual's adipostatic system's compensatory mechanisms and maintain significant weight loss? Changes in the entero-endocrine axis may offer part of the explanation. In 2002, Cummings et al. 43 showed that RYGB suppressed serum ghrelin concentration when compared with stable weight individuals, despite significant weight loss. In contrast, a second group that had lost weight by dieting had significantly increased serum ghrelin concentration when compared with stable weight individuals. Since then, there have been numerous studies looking at serum ghrelin levels after RYGB. Well-designed prospective studies have shown a reduction, 44 no change, 45 and an increase in serum ghrelin 46 following RYGB. The causes for the differences in published serum ghrelin levels after RYGB are unknown, but have been variously ascribed to dissimilarity in the surgical treatment of the fundus of the stomach, disruption of vagal innervation to the gastrointestinal tract, and levels of pre-surgical hyperinsulinaemia. 12, 27, 47 The importance of changes in serum ghrelin levels after RYGB is unknown. Individuals who have undergone RYGB show an exaggerated PYY and GLP-1 response to a small test meal when compared with both lean and obese controls. 48 It is likely that the exaggerated PYY and GLP-1 responses contribute to the premature satiety reported, and therefore weight loss. During exogenous infusions, high concentrations of PYY are associated with nausea, 49 but whether this plays a role in weight loss following RYGB is unknown. Currently, there are no reports on oxyntomodulin levels following RYGB, and no change in CCK has been detected. Experimental evidence in humans has hinted that increased energy expenditure after RYGB may also contribute to weight loss, but this requires further investigation. 50 Gut hormones are important regulators of energy expenditure. Infusion of PYY has been shown to increase energy expenditure in humans, which may provide a mechanism by which RYGB could modulate energy expenditure. 51 It has been known for some time that individuals who have undergone RYGB have profoundly altered taste perception. In a retrospective cross-sectional study of RYGB patients by Tichansky et al., 52 82% of patients reported a change in the taste of food or beverage, of whom 92% described it as a decrease in the intensity of taste. In keeping with clinical observations, 68% developed aversions to certain foods. Changes in taste after RYGB are not explained by common mediators of taste, such as zinc deficiency, liver and kidney impairment, increasing age or glycaemic status. 53 Studies have also shown that following RYGB, taste acuity for bitter and sour foodstuffs are upregulated. The importance of changes in taste is unknown, but further research is required to clarify their role. They may play a substantial role as, when asked, 83% of patients agreed that alterations in taste led to better weight loss.
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The effect of tampering with vagal signalling on weight loss after RYGB has proved difficult to determine. Different surgical techniques lead to varied patterns of postoperative vagal innervation. Vagotomy has been reported to block or attenuate the orexigenic effects of ghrelin, 54 and the anorexigenic effects of PYY3-36 and GLP-1. 55 However, blocking vagal signalling alters gastrointestinal function considerably, so it is unclear to what degree the effects of vagotomy are hormonally mediated.
The mechanisms of weight loss after LAGB
Little is known about the mechanisms of weight loss following LAGB. Gastric restriction may play a role in reducing energy intake, but the lack of compensatory behaviour to weight loss implicates other processes. The rapid weight gain seen after reversal of the procedure also argues for physiological attenuation of appetite when the band is optimally inflated. It has been shown that despite an appropriate orexigenic decrease in serum leptin, 55 fasting and postprandial satiety are increased in LAGB patients. 56 It is possible that LAGB exerts its effects by poorly defined modulation of hormonal or, more likely, neural signalling arising from the stomach. The vagus nerve may play a part and taste has been implicated, but their roles are poorly defined. 52 What is clear, however, is that whatever the mechanism, these messages act powerfully to promote and maintain weight loss.
Conclusion
Individuals are thought to have a developmentally determined adipose 'set point', which when perturbed invokes robust compensatory changes in appetite and energy expenditure to offset the weight change and return the system to its set point. Bariatric surgery seems to have found the adipostatic system's Achilles heel, and hence may offer insights into the secret of long-term substantial weight loss. The altered endocrine response plays a part, and the alteration to short-term visceral feedback caused by revised vagal innervation may also be important. Whatever the mechanism, bariatric surgery seems to favourably affect the energy regulatory system at multiple levels, achieving a new, lower, adipostatic set point. In the context of our current search to find effective therapies to stem the rising tide of obesity, it seems we may have a cure. We just do not understand how it works yet.
